secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0001654954-22-016606
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech reports FY2022 net loss $17.55M; cash $7.09M; Phase 2 COVID ARDS positive
--------------------------------------------------------------------------------

- Net loss of $17.55M ($1.05 loss per share) vs $13.34M ($1.10) in FY2021.
- Total operating expenses decreased 22% to $18.37M from $23.68M year-over-year.
- Cash and equivalents $7.09M at Sept 30, 2022; subsequent private placement raised ~$3.0M.
- Phase 2 study of EB05 in COVID ARDS showed 84% reduction in risk of death vs placebo at 28 days.
- Phase 2b dermatology study fully enrolled; topline data expected within 4 weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495422016606/0001654954-22-016606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495422016606/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-016606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer